Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking.

Anti-HIV Agents / pharmacology Drug Resistance, Viral HIV Infections / drug therapy HIV-1 Humans Nanoparticles Reverse Transcriptase Inhibitors Rilpivirine Tissue Distribution
Aggregation-induced emission Antiretroviral therapy CD4(+) T cell tracking Drug biodistribution Monocyte-macrophage Rilpivirine Single-crystal x-ray diffraction

Journal

Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316

Informations de publication

Date de publication:
02 2020
Historique:
received: 26 08 2019
revised: 24 11 2019
accepted: 04 12 2019
pubmed: 23 12 2019
medline: 15 5 2021
entrez: 23 12 2019
Statut: ppublish

Résumé

Antiretroviral therapy (ART) has improved the quality and duration of life for people living with human immunodeficiency virus (HIV) infection. However, limitations in drug efficacy, emergence of viral mutations and the paucity of cell-tissue targeting remain. We posit that to maximize ART potency and therapeutic outcomes newer drug formulations that reach HIV cellular reservoirs need be created. In a step towards achieving this goal we harnessed the aggregation-induced emission (AIE) property of the non-nucleoside reverse transcriptase inhibitor rilpivirine (RPV) and used it as a platform for drug cell and subcellular tracking. RPV nanocrystals were created with endogenous AIE properties enabling the visualization of intracellular particles in cell and tissue-based assays. The intact drug crystals were easily detected in CD4

Identifiants

DOI: 10.1016/j.biomaterials.2019.119669 PMID: 31865227 PMC: PMC7334833
pubmed: 31865227
pii: S0142-9612(19)30768-9
doi: 10.1016/j.biomaterials.2019.119669
pmc: PMC7334833
mid: NIHMS1591205
pii:
doi:

Substances chimiques

Anti-HIV Agents 0
Reverse Transcriptase Inhibitors 0
Rilpivirine FI96A8X663

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

119669

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS036126
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH115860
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103427
Pays : United States
Organisme : NIDA NIH HHS
ID : P01 DA028555
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062261
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA036727
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG043540
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS034239
Pays : United States
Organisme : NINDS NIH HHS
ID : T32 NS105594
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM106397
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

J Phys Chem A. 2016 Jul 7;120(26):4490-504
pubmed: 27294534
Nat Biotechnol. 2000 Apr;18(4):410-4
pubmed: 10748521
Science. 1989 Jul 21;245(4915):305-8
pubmed: 2665081
J Pharm Sci. 2016 Dec;105(12):3471-3482
pubmed: 27771050
New Microbiol. 2017 Apr;40(2):75-79
pubmed: 28368071
Colloids Surf B Biointerfaces. 2018 Dec 1;172:372-379
pubmed: 30193196
Nat Immunol. 2015 Jun;16(6):584-9
pubmed: 25990814
Biomaterials. 2018 Dec;185:174-193
pubmed: 30245386
Science. 1997 Jun 20;276(5320):1857-61
pubmed: 9188531
Cell Immunol. 2009;254(2):142-8
pubmed: 18835599
Lancet. 2017 Sep 23;390(10101):1499-1510
pubmed: 28750935
Saudi Pharm J. 2016 Jul;24(4):386-404
pubmed: 27330370
Chem Sci. 2019 Mar 15;10(16):4497-4501
pubmed: 31057778
J Exp Med. 1968 Dec 1;128(6):1309-25
pubmed: 5688078
Eur J Pharm Biopharm. 2009 Aug;72(3):502-8
pubmed: 19328850
Curr Opin HIV AIDS. 2015 Jul;10(4):253-7
pubmed: 26049950
AIDS. 2012 Jun 19;26(10):1261-8
pubmed: 22472858
Nat Commun. 2018 Apr 23;9(1):1597
pubmed: 29686427
Chem Commun (Camb). 2009 Aug 7;(29):4332-53
pubmed: 19597589
Nat Rev Microbiol. 2016 Jan;14(1):55-60
pubmed: 26616417
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
J Immunol. 2007 May 15;178(10):6404-15
pubmed: 17475870
Chem Rev. 2015 Nov 11;115(21):11718-940
pubmed: 26492387
Nat Commun. 2019 Jul 2;10(1):2753
pubmed: 31266936
Retrovirology. 2015 Jan 22;12:5
pubmed: 25608975
Infect Dis Clin North Am. 2014 Sep;28(3):371-402
pubmed: 25151562
Chem Commun (Camb). 2018 Jul 24;54(60):8371-8374
pubmed: 29995046
J Phys Chem A. 2014 Oct 2;118(39):9094-104
pubmed: 24921662
Biomaterials. 2019 Nov;222:119441
pubmed: 31472458
Biomaterials. 2014 Jan;35(1):590-600
pubmed: 24125775
Curr Med Chem. 2019;26(21):4042-4064
pubmed: 29484973
Curr Opin HIV AIDS. 2013 Nov;8(6):565-71
pubmed: 24100877
Nat Med. 2003 Jun;9(6):727-8
pubmed: 12754504
Expert Rev Mol Diagn. 2013 Jul;13(6):567-80
pubmed: 23895127
Methods Mol Biol. 2013;991:47-55
pubmed: 23546658
Biomaterials. 2018 Jan;151:53-65
pubmed: 29059541
Expert Opin Drug Deliv. 2011 Apr;8(4):415-33
pubmed: 21348773
Theranostics. 2018 Jan 1;8(1):256-276
pubmed: 29290806
Cell Rep. 2018 Aug 21;24(8):2088-2100
pubmed: 30134170
ACS Nano. 2017 Mar 28;11(3):2428-2443
pubmed: 28040885
Acta Crystallogr C Struct Chem. 2015 Jan;71(Pt 1):3-8
pubmed: 25567568
Adv Mater. 2014 Aug 20;26(31):5429-79
pubmed: 24975272
J Infect Dis. 1999 Mar;179(3):717-20
pubmed: 9952385
J Intern Med. 2011 Dec;270(6):550-60
pubmed: 21929712
J Am Chem Soc. 2012 Oct 31;134(43):17972-81
pubmed: 23043485
Chem Soc Rev. 2011 Nov;40(11):5361-88
pubmed: 21799992
J Neuroimmune Pharmacol. 2011 Dec;6(4):658-75
pubmed: 21789505
J Virol. 2007 Mar;81(6):2700-12
pubmed: 17182671
AIDS Care. 2010 Oct;22(10):1189-94
pubmed: 20640958
Acta Endocrinol Suppl (Copenh). 1975;194:245-61
pubmed: 1092116
Cancer. 1965 Apr;18:522-9
pubmed: 14278051
J Control Release. 2017 Dec 10;267:214-222
pubmed: 28844755
Antimicrob Agents Chemother. 2010 May;54(5):2042-50
pubmed: 20160045
Biofizika. 2014 Mar-Apr;59(2):231-7
pubmed: 25702473
Virology. 2007 Feb 5;358(1):148-58
pubmed: 16997345
J Virol. 2014 Sep 1;88(17):9504-13
pubmed: 24920821
Front Immunol. 2018 Jan 25;9:43
pubmed: 29422895
Nat Mater. 2014 Feb;13(2):125-38
pubmed: 24452356
Nature. 1988 Mar 31;332(6163):469-70
pubmed: 3281026
AIDS. 2014 Apr 24;28(7):989-97
pubmed: 24508782
ACS Appl Mater Interfaces. 2018 Apr 18;10(15):12189-12216
pubmed: 29043778
J Antimicrob Chemother. 2013 May;68(5):1169-78
pubmed: 23335199
Nat Commun. 2018 Feb 6;9(1):443
pubmed: 29402886
Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22
pubmed: 18156677
Nanomedicine (Lond). 2011 Aug;6(6):975-94
pubmed: 21417829
Antiviral Res. 2010 Jan;85(1):286-94
pubmed: 19808057
Theranostics. 2020 Jan 1;10(2):630-656
pubmed: 31903142
AIDS. 2014 Sep 24;28(15):2175-87
pubmed: 25144219
J Control Release. 2019 Oct;311-312:201-211
pubmed: 31491432

Auteurs

Insiya Z Mukadam (IZ)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA.

Jatin Machhi (J)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.

Jonathan Herskovitz (J)

Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.

Mahmudul Hasan (M)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA.

Maxim D Oleynikov (MD)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.

Wilson R Blomberg (WR)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.

Denis Svechkarev (D)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA.

Aaron M Mohs (AM)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA.

You Zhou (Y)

Center for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE, USA.

Prasanta Dash (P)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.

JoEllyn McMillan (J)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.

Santhi Gorantla (S)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.

Jered Garrison (J)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA.

Howard E Gendelman (HE)

Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA; Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA; Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA. Electronic address: hegendel@unmc.edu.

Bhavesh D Kevadiya (BD)

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Antirétroviraux › Agents antiVIH › Rilpivirine-associated aggregation-induced...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance virale aux médicaments › Rilpivirine-associated aggregation-induced...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Rilpivirine-associated aggregation-induced...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Rilpivirine-associated aggregation-induced...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Rilpivirine-associated aggregation-induced...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Rilpivirine-associated aggregation-induced...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Inhibiteurs de la transcriptase inverse › Rilpivirine-associated aggregation-induced...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Rilpivirine › Rilpivirine-associated aggregation-induced...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Distribution tissulaire › Rilpivirine-associated aggregation-induced...